Table 1 Patient characteristics with nivolumab in recurrent or metastatic head and neck cancer.
Variables | N (= 126) | % |
|---|---|---|
Age | ||
< 69 | 67 | 53 |
≥ 69 | 59 | 47 |
Sex | ||
Male | 104 | 83 |
Female | 22 | 17 |
Primary tumor site | ||
Oral cavity | 12 | 9 |
Nasopharynx | 11 | 9 |
Oropharynx | 27 | 21 |
Hypopharynx | 20 | 16 |
Larynx | 21 | 17 |
Sinonasal cavity | 13 | 10 |
Salivary gland | 8 | 6 |
External ear canal | 7 | 6 |
Unknown | 7 | 6 |
ECOG PS | ||
01 | 102 | 81 |
2–3 | 24 | 19 |
Site of recurrence | ||
Loco-regional | 54 | 43 |
Distant | 72 | 57 |
Platinum sensitivity | ||
Sensitive | 58 | 46 |
Refractory | 68 | 54 |
Modified Glasgow Prognostic Score | ||
0 | 70 | 56 |
1 | 12 | 10 |
2 | 35 | 27 |
Unknown | 9 | 7 |
Relative eosinophil count | ||
< 1.5 | 71 | 56 |
≥ 1.5 | 53 | 42 |
Unknown | 2 | 2 |
Neutrophil/lymphocyte ratio | ||
< 5 | 71 | 56 |
≥ 5 | 53 | 43 |
Unknown | 1 | 1 |
Platelet/lymphocyte ratio | ||
< 253 | 62 | 49 |
≥ 253 | 63 | 50 |
Unknown | 1 | 1 |
